© Reuters. FILE PHOTO: A compagny logo is seen at a Pfizer office in Puurs, Belgium, December 2, 2022. REUTERS/Johanna Geron   PFE -0.55% Add to/Remove from a Portfolio Add to Watchlist Add Position

Position added successfully to:

Please name your holdings portfolio Type: BUY SELL Date:   Amount: Price Point Value: Leverage: 1:1 1:10 1:25 1:50 1:100 1:200 1:400 1:500 1:1000 Commission:   Create New Watchlist Create Create a new holdings portfolio Add Create + Add another position Close PFIZ34 -0.93% Add to/Remove from a Portfolio Add to Watchlist Add Position

Position added successfully to:

Please name your holdings portfolio Type: BUY SELL Date:   Amount: Price Point Value: Leverage: 1:1 1:10 1:25 1:50 1:100 1:200 1:400 1:500 1:1000 Commission:   Create New Watchlist Create Create a new holdings portfolio Add Create + Add another position Close

(Reuters) – Pfizer Inc (NYSE:PFE) on Tuesday forecast 2023 sales of its COVID-19 products that fell short of Wall Street expectations, hit by lower demand in international markets and slower uptake of booster vaccines.

The U.S. drugmaker said it expects sales of $13.5 billion from the vaccine for 2023, below Refinitiv estimates of $14.39 billion, and projected $8 billion in sales of its antiviral pill, Paxlovid, short of $10.33 billion the Street expects.

Pfizer forecasts 2023 sales of COVID products below estimates